Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
Key Highlights
- ➤CAPTIVATE interim analysis showed 75% response rate among first 40 Part A participants
- ➤Dianthus (DNTH) announced one oral and four poster presentations at AANEM
- ➤Claseprubart received FDA Orphan Drug Designation for Myasthenia Gravis in May 2026
- ➤Dianthus (DNTH) expects MoMeNtum top-line data in December ’26
- ➤EMERGE Phase 3 top-line generalized Myasthenia Gravis results expected in 2H’28
Expert Statements
Tuan Vu, MD, Professor of Neurology at the University of South Florida Morsani College of Medicine
“Despite important advances in the treatment of generalized myasthenia gravis, there remains a need for therapies that can provide consistent disease control while reducing the treatment burden for patients. The sustained efficacy results and continued favorable safety profile observed for claseprubart in the Phase 2 MaGic open-label extension are encouraging and support its continued development as a potential differentiated treatment option for patients with gMG.”
Richard Lewis, MD, Professor of Neurology at Cedars-Sinai
“For people living with CIDP, functional impairment can have a substantial impact on everyday life, underscoring the need for new treatment options beyond IVIG. The 75% response rate observed in the interim responder analysis of the first 40 participants completing unblinded Part A of the Phase 3 CAPTIVATE trial is encouraging, particularly given the consistent and clinically meaningful improvements demonstrated across multiple measures of function and disability in a broad patient population with varied prior treatment experience. These findings highlight the potential for claseprubart to offer a new approach to the treatment of CIDP.”
NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place September 29 to October 2, 2026 in Orlando, Florida.
“Despite important advances in the treatment of generalized myasthenia gravis, there remains a need for therapies that can provide consistent disease control while reducing the treatment burden for patients,” said Tuan Vu, MD, Professor of Neurology at the University of South Florida Morsani College of Medicine. “The sustained efficacy results and continued favorable safety profile observed for claseprubart in the Phase 2 MaGic open-label extension are encouraging and support its continued development as a potential differentiated treatment option for patients with gMG.”
Get started
Create a free account to read the full story.